Melatonin (MLT) is a methoxyindole secreted principally by the pineal gland. It is synthesized at night under normal environmental conditions. The endogenous rhythm of secretion is generated by the suprachiasmatic nuclei and entrained by the light/dark cycle. Light is able to both suppress or entrain MLT production on light schedule. The nyctohemeral rhythm of this hormone can be determined by repeated measurement of plasma or saliva MLT or urine sulfatoxy-MLT, the main hepatic metabolite. MLT can be considered as the output (the hand) of the endogenous clock. Since the regulating system follows a central and sympathetic nervous pathway, an abnormality at any level could unspecifically modify the MLT secretion, especially in patients with sympathalgia or dysautonomia. MLT plays the role of an endogenous zeitgeber on core temperature or sleep-wake cycle. Exogenous MLT is able to influence the endogenous secretion of the hormone according to a phase-response curve. There are practical implications for this property in situations when biological rhythms are disturbed (jet-lag syndrome, delayed sleep phase syndrome, insomnia in blind people, shift-work, insomnia in elderly people). Improvement of pharmaceutical forms (controlled release preparations) or development of MLT analogs could lead to decisive progress.

Keywords:
Melatonin, Biological rhythms, Circadian clock, Humans
1.
Lerner AB, Case JD, Takakashi Y, Lee TH, Mori W: Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958;80:2587.
2.
Trinchard-Lugan I, Waldhauser F: The short-term secretion pattern of human serum melatonin indicates apulsatile hormone release. J Clin Endocrinol Metab 1989;69:663–669.
3.
Claustrat B, Brun J, Garry P, Roussel B, Sassolas G: A once-repeated study of nocturnal plasma melatonin patterns and sleep recordings in six normal young men. J Pineal Res 1986;3:301–310.
4.
Iguchi H, Kato KI, Ibayashi H: Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. J Clin Endocrinol Metab 1982;54:1025–1027.
5.
Mallo C, Zaidan R, Galy G, Vermeulen E, Brun J, Chazot G, Claustrat B: Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol 1990;38:297–301.
6.
Goldman BD, Darrow JM: The pineal gland and mammalian photoperiodism. Neuroendocrinology 1983;37:386–396.
7.
Touitou Y, Fevre M, Lagoguey M, Carayon A, Bogdan A, Reinberg A, Beck H, Cesselin F, Touitou C: Age- and mental health-related circadian rhythms of plasma levels of melatonin, prolactin, luteinizing hormone and follicle-stimulating hormone in man. J Endocrinol 1981;91:467–475.
8.
Lydic R, Schoene WC, Czeisler CA, Moore-Ede MC: Suprachiasmatic region of the human hypothalamus: Homolog to the primate circadian pacemaker? Sleep 1980;2:355–361.
9.
Edgar DM, Dement WC, Fuller CA: Effect of SCN lesions on sleep in squirrel monkeys: Evidence for opponent processes in sleep-wake regulation. J Neurosci 1993;13:1065–1079.
10.
Moore RY: The innervation of the mammalian pineal gland; in Reiter RJ (ed): The Pineal and Reproduction. Basel, Karger, 1978, pp 1–29.
11.
Klein DC, Moore RY: Pineal N-acetyltransferase and hydroxyindole-o-methyltransferase: Control by the retinohypothalamic tract and the suprachiasmatic nucleus. Brain Res 1979;174:245–262.
12.
Pardridge WM, Mietus LJ: Transport of albumin-bound melatonin through the blood-brain barrier. J Neurochem 1980;34:1761–1763.
13.
Reppert SM, Weaver DR, Rivkees SA, Stopa EG: Putative melatonin receptors in a human biological clock. Science 1988;242:78–91.
14.
Shibata S, Cassone VM, Moore RY: Effects of melatonin on neuronal activity in the rat suprachiasmatic nucleus in vitro. Neurosci Lett 1989;97:140–144.
15.
McArthur AJ, Gillette MU, Prosser RA: Melatonin directly resets the rat suprachiasmatic circadian clock in vitro. Brain Res 1991;565:158–161.
16.
O’Brien IAD, Lewin IG, O’Hare JP, Arendt J, Corral RJM: Abnormal circadian rhythm of melatonin in diabetic autonomic neuropathy. Clin Endocrinol 1986;24:359–364.
17.
Chazot G, Claustrat B, Brun J, Jordan D, Sassolas G, Schott B: A chronobiological study of melatonin, cortisol growth hormone and prolactin secretion in cluster headache. Cephalalgia 1984;4:213–220.
18.
Waldenlind E, Gustafsson SA, Ekbom K, Wetterberg L: Circadian secretion of cortisol and melatonin in cluster headache during active cluster periods and remission. J Neurol Neurosurg Psychiatry 1987;50:207–213.
19.
Claustrat B, Buguet A, Geoffriau M, Montmayeur A, Bogui P, Muanga G, Stanghellini R, Dumas M: Circadian plasma melatonin rhythm is maintained in human African trypanosomiasis. Eurosleep ’94, 12th Congress of the European Sleep Research Society, Firenze, May 22–27, 1994.
20.
Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP: Light suppresses melatonin secretion in humans. Science 1980;210:1267–1269.
21.
Horne JA, Donlon J, Arendt J: Green light attenuates melatonin output and sleepiness during sleep deprivation. Sleep 1991;14:233–240.
22.
Buresova M, Dvorakova M, Zvolsky P, Illnerova H: Early morning bright light phase advances the human circadian pacemaker within one day. Neurosci Lett 1991;121:47–50.
23.
Kauppila A, Kivela A, Pakarinen A, Vakkuri O: Inverse seasonal relationship between melatonin and ovarian activity in humans in a region with a strong seasonal contrast in luminosity. J Clin Endocrinol Metab 1987;65:823–828.
24.
Lewy AJ, Sack RL: The dim light melatonin onset as a marker for circadian phase position. Chronobiol Int 1989;6:93–102.
25.
Shanahan TL, Czeisler CA: Light exposure induces equivalent phase shifts of the endogenous circadian rhythms of circulating plasma melatonin and core body temperature in men. J Clin Endocrinol Metab 1991;73:227–235.
26.
Zaidan R, Geoffriau M, Brun J, Taillard J, Bureau C, Chazot G, Claustrat B: Melatonin is able to influence its secretion in humans: Description of a phase-response curve. Neuroendocrinology 1994;60:105–112.
27.
Deacon S, Arendt J: Posture influences melatonin concentrations in plasma and saliva in humans. Neurosci Lett 1994;167:191–194.
28.
Armstrong SM: Melatonin: The internal zeitgeber of mammals? Pineal Res Rev 1989;7:157–202.
29.
Strassmann RJ, Qualls CR, Lisansky EJ, Peake GT: Elevated rectal temperature produced by all-night bright light is reversed by melatonin infusion in men. J Appl Physiol 1991;71:2178–2182.
30.
Akerstedt T, Froberg JE, Friberg Y, Wetterberg L: Melatonin excretion, body temperature and subjective arousal during 64 hours of sleep deprivation. Psychoneuroendocrinology 1979;4:219–225.
31.
Wehr TA: The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). J Clin Endocrinol Metab 1991;73:1276–1280.
32.
Campbell SS, Dawson D: Enhancement of nighttime alertness and performance with bright ambient light. Physiol Behav 1990;48:317–320.
33.
Bougrine S, Cabon P, Ignazi G, Geoffriau M, Brun J, Claustrat B: Phase delay of rhythm of 6-sulfatoxy-melatonin excretion by bright light improves sleep and performance; in Touitou Y, Arendt J, Pévet P (eds): Melatonin and the Pineal Gland – From Basic Science to Clinical Application. Amsterdam, Elsevier Science, 1993, pp 219–223.
34.
Haimov I, Laudon M, Zisapel N, Souroujon M, Nof D, Shlitner A, Herer P, Tzischinsky O, Lavie P: Sleep disorders and melatonin rhythms in elderly people. BMJ 1994;309:167.
35.
Wirz-Justice A, Armstrong SM: Melatonin: Nature’s soporific? J Sleep Res 1996;5:137–141.
36.
Lewy AJ, Ahmed S, Latham Jackson JM, Sack RL: Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992;9:380–392.
37.
Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD: Delayed sleep phase syndrome response to melatonin. Lancet 1991;337:1121–1124.
38.
Arendt J, Aldhous M, Wright J: Synchronisation of a disturbed sleep-wake cycle in a blind man by melatonin treatment. Lancet 1988;i:772–773.
39.
Folkard S, Arendt J, Clark M: Can melatonin improve shift-workers’ tolerance of the night shift? Some preliminary findings. Chronobiol Int 1993;10:315–320.
40.
Arendt J, Aldhous M, Marks V: Alleviation of jet lag by melatonin: Preliminary results of controlled double-blind trial. Br Med J 1986;292:1170.
41.
Claustrat B, Brun J, David M, Sassolas G, Chazot G: Melatonin and jet lag: Confirmatory result using a simplified protocol. Biol Psychiatry 1992;32:705–711.
42.
Petrie K, Conaglen JV, Thompson L, Chamberlain K: Effect of melatonin on jet lag after long-haul flights. BMJ 1989;298:705–707.
43.
Broadway J, Arendt J, Folkard S: Bright light phase shifts the human melatonin rhythm during the Antarctic winter. Neurosci Lett 1987;79:185–189.
44.
Morgan PJ, Barrett P, Howell E, Helliwell R: Melatonin receptors: Localization, molecular pharmacology and physiological significance. Neurochem Int 1994;24:101–146.
45.
Schrader M, Danielsson C, Wiesenberg I, Carlberg C: Identification of natural monomeric response elements of the nuclear receptor RZR/ROR. J Biol Chem 1996;271:19732–19736.
46.
Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ: Melatonin: A potent, endogenous hydroxyl radical scavenger. Endocr J 1993;1:57–60.
47.
Tan DX, Reiter RJ, Chen LD, Poeggeler B, Manchester LC, Barlow-Walden LR: Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the chemical carcinogen safrole. Carcinogenesis 1994;15:215–218.
48.
Benes L, Brun J, Claustrat B, Degrande G, Ducloux N, Geoffriau M, Horriere F, Karsenty H, Lagain D: Plasma melatonin (M) and sulfatoxy-melatonin (aMT6s) kinetics after transmucosal administration to humans; in Touitou Y, Arendt J, Pévet P (eds): Melatonin and the Pineal Gland – From Basic Science to Clinical Application. Amsterdam, Elsevier Science, 1993, pp 347–350.
49.
Depreux P, Lesieur D, Ait Mansour H, Morgan P, Howell HE, Renard P, Caignard DH, Pfeiffer B, Delagrange P, Guardiola B, Yous S, Demarque A, Adam G, Andrieux J: Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J Med Chem 1994;37:3231–3239.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.